The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Drop the price to fill a large order - seems pretty straightforward to me
Yep, can't even but small amounts
Seems to be
Some serious money going in now
Well 0.002 rounded to two decimal places will show as 0.00
Very positive indeed
Could really balloon today
Fundamentalanalysis thank you so much for letting us know
A lot of them showing as sales were buys for sure
NICE to evaluate the Genedrive ® MT-RNR1 Test under their Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has started an evaluation of the Genedrive® MT-RNR1 test via their Diagnostics Assessment Programme ('DAP'). DAP evaluations are designed to provide robust recommendations on the use of new products, which is presented in the form of NICE guidance, and to promote rapid and consistent adoption of clinically innovative and cost-effective diagnostic technologies in the NHS.
An independent advisory committee considers the evidence provided, makes draft recommendations for public consultation and ultimately makes final recommendations for publication in NICE guidance. The guidance produced is used by NHS commissioners, practitioners, healthcare operational managers and purchasing and procurement organisations .
genedrive's assay is the world's first rapid point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive® MT-RNR1 test.
David Budd, CEO of genedrive plc, said: "We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive® MT-RNR1 test was selected for this programme following successful publication of the NICE Medtech innovation briefing ("MIB290") in March. The NICE guidance is an important element required to drive uptake and adoption of the test in the NHS by demonstrating the cost-saving efficiencies. The application of Genedrive's technology shows how a rapid, affordable, point-of-care test could impact patients' treatment and quality of life."
For further details please contact:
genedrive plc
+44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO
Exactly, Jarv
Ridiculously misleading 21.43% current spread
#VAST has now published its presentation recording and written Q&A following Monday’s session on the @InvestorMeetCo platform – log in to your Investor Meet Company profile for full details.
https://t.co/ugCL5G8AnC
Yes ridiculous spread
Love how quickly this share turns around
Well that's better!
RTR Ereb was referring to green boxes.
If you thought you were one of his green boxes, then why reply to them since they won't see your response?
... gonna be interesting to see the way this goes today..
Most of the morning was a couple of million less buys than sells.
Now the cheapies being snapped up, and we've had a few million more buys than sales, but of course 22% down
Probably a bit of both